Moderate to severe COPD

A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD).

Register Today!

Trial Information

Trial Duration85 days
Number of Visits7
Lead CRCJason Collin

For additional information
on this trial contact: